1 Department of Medicine, McMaster University, 1200 Main St W, Rm 1P11, Hamilton, ON L8N 3Z5. Canada.
2 Department of Radiology, McMaster University, Hamilton, ON, Canada.
AJR Am J Roentgenol. 2018 Aug;211(2):246-259. doi: 10.2214/AJR.18.19822. Epub 2018 Jun 27.
In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field.
Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.
本文回顾了 PET/CT 在痴呆症管理中的文献,提出了最佳临床实践的证据,并讨论了该领域的最新进展。
痴呆症的标准影像学检查包括 CT 和 MRI,主要用于排除血管病变或肿块、检测萎缩以及监测疾病严重程度。PET/CT 是一种强大的功能模态,可以区分痴呆症类型并影响管理。氟-18-氟代脱氧葡萄糖(FDG)PET/CT 揭示了大脑中葡萄糖代谢的空间模式。最近,已经开发出用于 PET 的放射性示踪剂,这些示踪剂与淀粉样蛋白、tau 蛋白和神经炎症标志物结合。